R.R. Baliga/LinkedIn
Jul 1, 2026, 08:48
R.R. Baliga: The New JACC/ACC 2026 Statement Reinforces That DOAC Therapy Is Never One Size Fits All
R.R. Baliga, Editor-In-Chief of Textbook of Internal Medicine: Helping You Become a Great Doc, shared on LinkedIn:
”New JACC/ACC 2026 Scientific Statement spotlight: DOACs are now central to stroke and venous thromboembolism prevention—but not ‘one size fits all.’
The practical message: choose the right agent, dose correctly, avoid DOACs in mechanical valves and rheumatic mitral stenosis, reassess renal/liver function, bleeding risk, drug interactions, adherence, and cost.
In anticoagulation, the prescription is only the opening move; follow-up is where safety lives.”
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 13:53Honey Blankenship: United by a Shared Commitment to the Bleeding Disorders Community
-
Aug 16, 2026, 13:46Sagar Bejalwar: A Rare Bleeding Disorder and the Importance of Specialized Care
-
Aug 16, 2026, 13:39Sharun Khan: Advancing Regenerative Medicine Through Veterinary Translational Science
-
Aug 16, 2026, 13:21Francois Roubille: New ESC Consensus on Inflammation in Coronary Syndromes
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?